Comparison 15. Imipenem/cilastatin versus other carbapenems.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all causes ‐ ITT analysis))	3	528	Odds Ratio (M‐H, Random, 95% CI)	1.50 [0.58, 3.88]
2 Mortality (due to infection ‐ ITT analysis))	3	528	Odds Ratio (M‐H, Random, 95% CI)	1.79 [0.50, 6.42]
3 Clinical success	5	667	Odds Ratio (M‐H, Random, 95% CI)	1.04 [0.62, 1.77]
4 Clinical success (ITT analysis)	2	367	Odds Ratio (M‐H, Random, 95% CI)	0.61 [0.22, 1.65]
5 Microbiological success	4	575	Odds Ratio (M‐H, Random, 95% CI)	0.99 [0.53, 1.87]
6 Superinfection	2	258	Odds Ratio (M‐H, Random, 95% CI)	0.75 [0.26, 2.18]
7 Adverse reactions (ITT analysis)	4	810	Odds Ratio (M‐H, Random, 95% CI)	1.30 [0.81, 2.10]
7.1 Overall	4	810	Odds Ratio (M‐H, Random, 95% CI)	1.30 [0.81, 2.10]
8 Duration of treatment	1	135	Mean Difference (IV, Random, 95% CI)	‐1.10 [‐2.20, ‐0.00]
9 Days hospitalised	1	135	Mean Difference (IV, Random, 95% CI)	‐0.10 [‐4.52, 4.32]